Correlation of Genomic Variation in Enzymes Responsible for Metabolism of Capecitabine With Drug Metabolism

Summary

The goal of this clinical research study is to find out how gene expression (as well as how often this expression occurs) in patients with breast cancer affects how Xeloda® (capecitabine) is cleared (passed through the urine) from the body. The safety of capecitabine will also be studied.

Timeline

Start

2019-01

Primary completion

2021-01

Completion

2021-01

Outcome

Outcome not reported

Stopped: “Principal Investigator departed from institution”

Drugs

Indications